CN110183483A - 一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物及制备方法与应用 - Google Patents
一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物及制备方法与应用 Download PDFInfo
- Publication number
- CN110183483A CN110183483A CN201910369841.2A CN201910369841A CN110183483A CN 110183483 A CN110183483 A CN 110183483A CN 201910369841 A CN201910369841 A CN 201910369841A CN 110183483 A CN110183483 A CN 110183483A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- tin
- bis
- dimethylglyoxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FBIVKLDWLAMJMB-UHFFFAOYSA-N propyltin Chemical compound CCC[Sn] FBIVKLDWLAMJMB-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- JGUQDUKBUKFFRO-CIIODKQPSA-N dimethylglyoxime Chemical compound O/N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-CIIODKQPSA-N 0.000 title claims abstract 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 201000007270 liver cancer Diseases 0.000 claims abstract description 7
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 6
- 201000009030 Carcinoma Diseases 0.000 claims abstract description 4
- 201000005202 lung cancer Diseases 0.000 claims abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 229910052718 tin Inorganic materials 0.000 claims description 18
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 16
- 239000013078 crystal Substances 0.000 claims description 14
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 12
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 230000001093 anti-cancer Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 polytetrafluoroethylene Polymers 0.000 claims description 9
- CKXHZTXMENDKEZ-UHFFFAOYSA-N (2-methyl-2-phenylpropyl)tin Chemical compound [Sn]CC(C)(C)C1=CC=CC=C1 CKXHZTXMENDKEZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 229910020923 Sn-O Inorganic materials 0.000 claims description 6
- 238000002447 crystallographic data Methods 0.000 claims description 6
- 238000000921 elemental analysis Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000036961 partial effect Effects 0.000 claims description 6
- 238000002390 rotary evaporation Methods 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229910020813 Sn-C Inorganic materials 0.000 claims description 3
- 229910018732 Sn—C Inorganic materials 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- JGUQDUKBUKFFRO-UHFFFAOYSA-N chembl3184098 Chemical class ON=C(C)C(C)=NO JGUQDUKBUKFFRO-UHFFFAOYSA-N 0.000 claims 2
- 239000003560 cancer drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- JGUQDUKBUKFFRO-GGWOSOGESA-N (NE)-N-[(3E)-3-hydroxyiminobutan-2-ylidene]hydroxylamine Chemical compound O\N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-GGWOSOGESA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- AVSHTGDWDPCROU-UHFFFAOYSA-N ClC1=C(C[Sn])C=CC=C1 Chemical compound ClC1=C(C[Sn])C=CC=C1 AVSHTGDWDPCROU-UHFFFAOYSA-N 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- AYOHIQLKSOJJQH-UHFFFAOYSA-N dibutyltin Chemical compound CCCC[Sn]CCCC AYOHIQLKSOJJQH-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000012760 heat stabilizer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000003663 paint preservative agent Substances 0.000 description 1
- ODOPKAJVFRHHGM-UHFFFAOYSA-N phenyltin Chemical compound [Sn]C1=CC=CC=C1 ODOPKAJVFRHHGM-UHFFFAOYSA-N 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000011864 timber preservative Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2224—Compounds having one or more tin-oxygen linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种双[三(2‑甲基‑2‑苯基)丙基锡]丁二酮肟配合物,其特征在于,所述配合物如式1所示:本发明还公开了其制备方法和应用。本发明的有益效果在于:提供了一种全新的双[三(2‑甲基‑2‑苯基)丙基锡]丁二酮肟配合物,为癌症尤其是肝癌、肺癌、表皮癌、结肠癌或乳腺癌的后期药物制备提供了新的思路。
Description
技术领域
本发明属于配合物制备领域,具体涉及一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物及制备方法与应用。
背景技术
有机锡是一类含有Sn-C键的金属有机化合物,由于具有广泛的生物活性和较强的催化活性,可用作催化剂、热稳定剂、杀菌剂、防污涂料及木材防腐剂,在工业、农业、医药卫生等领域有广泛应用。人们在对金属抗癌药物的研究和筛选过程中,发现一些有机锡化合物具有比顺铂更高的抗肿瘤活性(Crowe,A.J.;Smith,P.J.;Atassi.G.,Chem.Biol.Interact.,1980,32,171.),自此,关于有机锡抗癌活性的研究越来越活跃,成为继顺铂之后的又一研究热点。
已有研究表明,有机锡化合物的生物活性与中心锡原子的配位状态有关,而中心锡原子的配位形式决定于直接与锡原子相连的烃基的结构和配体的类型。就烃基而言,环己基、正丁基和苯基锡化合物的抗癌活性较强,乙基次之,甲基则几乎无抗癌活性;实验也证明配体的结构对化合物的抗癌活性以及杀灭癌细胞的广谱性也起着重要的作用,有机锡羧酸酯化合物的生物活性往往比相应的其它类型的有机锡化合物高,如中国专利CN101402650B公开了一种二丁基锡与喹啉甲酸配合物在制备治疗胃癌、鼻咽癌、人肝癌或白血病的药物中应用;欧洲专利EP0177785B1公开的双[三(2-甲基-2-苯基丙基)锡]单羧酸酯比双[三(2-甲基-2-苯基丙基)锡]氧化物具有更强的生物活性;文献(高等学校化学学报,2008,29(9):1781-1785.)报道,二丁基锡羧酸酯对格兰氏阴性和阳性菌的抑制活性明显强于二丁基氧化锡,且在较低浓度下具有比二丁基氧化锡更强的抑制肿瘤作用;文献(无机化学学报,2011,27(1):107-113.)证明,三环己基锡羧酸酯具有比三环己基氢氧化锡更强的杀菌、抗癌活性。
发明内容
本发明的目的旨在于通过双[三(2-甲基-2-苯基丙基)锡]氧化物,与配体丁二酮二肟,在一定条件下反应,合成得到了对HUH7(人肝癌细胞)、A549(人肺癌细胞)、A431(人表皮癌细胞)、HCT-116(人结肠癌细胞)、MDA-MB-231(人乳腺癌细胞)具有较强抑制活性的化合物双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物,为开发抗癌药物提供了新途径。
为了实现本发明的目的,所采用的技术方案是:
一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物,其中,所述配合物如式1所示:
在本发明的一个优选实施例中,所述配合物的表征数据为:熔点:116-118℃;IR(KBr,cm-1):3070.21,2958.80,2989.01ν(C-H),557.43ν(Sn-O),509.21ν(Sn-C);元素分析(C64H84N2O2Sn2),计算值(%):C,66.80;H,7.36;N,2.43。实测值(%):C,66.72;H,7.33;N,2.46;晶体学数据:晶体属单斜晶系,空间群P21/n,晶体学参数:a=1.9596(3)nm,b=0.138818(9)nm,c=1.7543(2)nm,α=γ=90°,β=115.050(2)°,Z=2,V=2.9922(7)nm3;化合物为双锡核分子,锡原子均为四配位的畸变四面体构型。
在本发明的一个优选实施例中,所述配合物具有一定的热稳定范围,在260℃以下能稳定存在。
为了实现本发明的目的,所采用的又一技术方案是:
一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物的制备方法,包括如下步骤:
在聚四氟乙烯微波反应罐中,加入甲醇,双[三(2-甲基-2-苯基丙基)锡]氧化物、丁二酮二肟,将罐盖密封好,置于微波反应器中。设置微波有机合成系统温度110-130℃,微波辐射反应1.5-2.5h。旋转蒸发除去部分溶剂,放置析出白色固体,用苯重结晶得无色晶体双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物。
在本发明的一个优选实施例中,所述[三(2-甲基-2-苯基丙基)锡]氧化物和丁二酮二肟的摩尔比为1:1。
在本发明的一个优选实施例中,所述甲醇的加入量为25-35mL。
在本发明的一个优选实施例中,所述微波有机合成系统温度为120℃。
在本发明的一个优选实施例中,所述微波辐射反应2h。
为了实现本发明的目的,所采用的又一技术方案是:
一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物在制备抗癌药物组合物中的应用。
在本发明的一个优选实施例中,所述癌包括肝癌、肺癌、表皮癌、结肠癌、乳腺癌中的任意一种。
本发明的有益效果在于:
提供了一种全新的双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物,为癌症尤其是肝癌、肺癌、表皮癌、结肠癌或乳腺癌的后期药物制备提供了新的思路。
附图说明
图1为配合物的晶体结构图。
图2为配合物的红外光谱图。
图3为配合物的热稳定图。
具体实施方式
实施例1
在聚四氟乙烯微波反应罐中,加入30mL甲醇,01.052g(1mmol)双[三(2-甲基-2-苯基丙基)锡]氧化物、0.116g(1mmol)丁二酮二肟,将罐盖密封好,置于微波反应器中。设置微波有机合成系统温度120℃,微波辐射反应2h。旋转蒸发除去部分溶剂,放置析出白色固,用苯重结晶得无色晶体双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物0.944g,产率82%。
熔点:118℃。
IR(KBr,cm-1):3070.21,2958.80,2989.01ν(C-H),557.43ν(Sn-O),509.21ν(Sn-C)。
元素分析(C64H84N2O2Sn2),计算值(%):C,66.80;H,7.36;N,2.43。实测值(%):C,66.72;H,7.33;N,2.46。
晶体学数据:晶体属单斜晶系,空间群P21/n,晶体学参数:a=1.9596(3)nm,b=0.138818(9)nm,c=1.7543(2)nm,α=γ=90°,β=115.050(2)°,Z=2,V=2.9922(7)nm3;化合物为双锡分子,锡原子分别为四配位的畸变四面体构型。
实施例2
在聚四氟乙烯微波反应罐中,加入30mL甲醇,01.051g(1mmol)双[三(2-甲基-2-苯基丙基)锡]氧化物、0.115g(1mmol)丁二酮二肟,将罐盖密封好,置于微波反应器中。设置微波有机合成系统温度120℃,微波辐射反应2h。旋转蒸发除去部分溶剂,放置析出白色固,用苯重结晶得无色晶体双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物0.943g,产率81%。
熔点:116℃。
IR(KBr,cm-1):3070.21,2958.80,2989.01ν(C-H),557.43ν(Sn-O),509.21ν(Sn-C)。
元素分析(C64H84N2O2Sn2),计算值(%):C,66.80;H,7.36;N,2.43。实测值(%):C,66.72;H,7.33;N,2.46。
晶体学数据:晶体属单斜晶系,空间群P21/n,晶体学参数:a=1.9596(3)nm,b=0.138818(9)nm,c=1.7543(2)nm,α=γ=90°,β=115.050(2)°,Z=2,V=2.9922(7)nm3;化合物为双锡分子,锡原子分别为四配位的畸变四面体构型。
实施例3
在聚四氟乙烯微波反应罐中,加入30mL甲醇,01.053g(1mmol)双[三(2-甲基-2-苯基丙基)锡]氧化物、0.115g(1mmol)丁二酮二肟,将罐盖密封好,置于微波反应器中。设置微波有机合成系统温度120℃,微波辐射反应2h。旋转蒸发除去部分溶剂,放置析出白色固,用苯重结晶得无色晶体双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物0.945g,产率81%。
熔点:118℃。
IR(KBr,cm-1):3070.21,2958.80,2989.01ν(C-H),557.43ν(Sn-O),509.21ν(Sn-C)。
元素分析(C64H84N2O2Sn2),计算值(%):C,66.80;H,7.36;N,2.43。实测值(%):C,66.72;H,7.33;N,2.46。
晶体学数据:晶体属单斜晶系,空间群P21/n,晶体学参数:a=1.9596(3)nm,b=0.138818(9)nm,c=1.7543(2)nm,α=γ=90°,β=115.050(2)°,Z=2,V=2.9922(7)nm3;化合物为双锡分子,锡原子分别为四配位的畸变四面体构型。
实施例4
在聚四氟乙烯微波反应罐中,加入30mL甲醇,01.053g(1mmol)双[三(2-甲基-2-苯基丙基)锡]氧化物、0.116g(1mmol)丁二酮二肟,将罐盖密封好,置于微波反应器中。设置微波有机合成系统温度120℃,微波辐射反应2h。旋转蒸发除去部分溶剂,放置析出白色固,用苯重结晶得无色晶体双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物0.943g,产率81%。
熔点:117℃。
IR(KBr,cm-1):3070.21,2958.80,2989.01ν(C-H),557.43ν(Sn-O),509.21ν(Sn-C)。
元素分析(C64H84N2O2Sn2),计算值(%):C,66.80;H,7.36;N,2.43。实测值(%):C,66.72;H,7.33;N,2.46。
晶体学数据:晶体属单斜晶系,空间群P21/n,晶体学参数:a=1.9596(3)nm,b=0.138818(9)nm,c=1.7543(2)nm,α=γ=90°,β=115.050(2)°,Z=2,V=2.9922(7)nm3;化合物为双锡分子,锡原子分别为四配位的畸变四面体构型。
体外抗癌测试:
双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物,其体外抗癌活性测定是通过MTT实验方法实现的。
采用MTT法检测了二(硫代水杨酸甲酯)二(邻氯苄基)锡配合物对人肝癌细胞(HUH7)、人肺癌细胞(A549)、表皮癌细胞(A431)、结肠癌细胞(HCT-116)、乳腺癌细胞(231)的体外抗性肿瘤活性。将化合物用二甲基亚砜(DMSO)配成5.0mg/mL的溶液,用RPMI-1640培养基分别稀释成5,10,25,50,100 g/mL。取处于指数生长期的HeLa细胞悬液加至96孔板中(细胞浓度为50000个/mL,100μL/孔),于37℃、5%CO2恒温箱中培养12-18h使细胞贴壁。去除上清,加100μL不同浓度的上述化合物,每个浓度设4个复孔,孵育24h,弃去上清,每孔加入2.0mg/mL的MTT溶液60μL,继续培养3h,除上清后,每孔加入150μL二甲基亚砜,低速振荡10min,使深蓝色结晶溶解,用酶标仪在490nm波长处测其吸光度值。按如下公式计算各组对癌细胞的抑制率:抑制率(%)=(对照组OD值-测试组OD值)/对照组OD值×100%。每组实验均重复3次,取其平均值。
以试样浓度对数值与细胞抑制率作线性回归,用spss17.0软件计算试样对细胞的半抑制浓度(IC50值),活性数据见表1。
表1二(硫代水杨酸甲酯)二(邻氯苄基)锡配合物抗癌药物体外活性测试数据
表1说明了该全新的配合物具有很好的抗癌活性,适合于后期抗癌药的开发。
Claims (10)
1.一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物,其特征在于,所述配合物如式1所示:
2.如权利要求1所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物,其特征在于,所述配合物的表征数据为:熔点:116-118℃;IR(KBr,cm-1):3070.21,2958.80,2989.01ν(C-H),557.43ν(Sn-O),509.21ν(Sn-C);元素分析(C64H84N2O2Sn2),计算值(%):C,66.80;H,7.36;N,2.43。实测值(%):C,66.72;H,7.33;N,2.46;晶体学数据:晶体属单斜晶系,空间群P21/n,晶体学参数:a=1.9596(3)nm,b=0.138818(9)nm,c=1.7543(2)nm,α=γ=90°,β=115.050(2)°,Z=2,V=2.9922(7)nm3;化合物为双锡核分子,锡原子均为四配位的畸变四面体构型。
3.如权利要求1所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物,其特征在于,所述配合物具有一定的热稳定范围,在260℃以下能稳定存在。
4.如权利要求1-3当中任意一项所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物的制备方法,其特征在于,包括如下步骤:
在聚四氟乙烯微波反应罐中,加入甲醇,双[三(2-甲基-2-苯基丙基)锡]氧化物、丁二酮二肟,将罐盖密封好,置于微波反应器中。设置微波有机合成系统温度110-130℃,微波辐射反应1.5-2.5h。旋转蒸发除去部分溶剂,放置析出白色固体,用苯重结晶得无色晶体双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物。
5.如权利要求4所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物的制备方法,其特征在于,所述[三(2-甲基-2-苯基丙基)锡]氧化物和丁二酮二肟的摩尔比为1:1。
6.如权利要求4所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物的制备方法,其特征在于,所述甲醇的加入量为25-35mL。
7.如权利要求4所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物的制备方法,其特征在于,所述微波有机合成系统温度为120℃。
8.如权利要求4所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物的制备方法,其特征在于,所述微波辐射反应2h。
9.如权利要求1-3当中任意一项所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物在制备抗癌药物组合物中的应用。
10.如权利要求9所述的一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物在制备抗癌药物组合物中的应用,其特征在于,所述癌包括肝癌、肺癌、表皮癌、结肠癌、乳腺癌中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910369841.2A CN110183483A (zh) | 2019-05-06 | 2019-05-06 | 一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物及制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910369841.2A CN110183483A (zh) | 2019-05-06 | 2019-05-06 | 一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物及制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110183483A true CN110183483A (zh) | 2019-08-30 |
Family
ID=67715686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910369841.2A Pending CN110183483A (zh) | 2019-05-06 | 2019-05-06 | 一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物及制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110183483A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282672A (en) * | 1962-04-09 | 1966-11-01 | Monsanto Co | Method for preventing plant growth |
US3419662A (en) * | 1962-04-09 | 1968-12-31 | Monsanto Co | Method of inhibiting the growth of bacteria and fungi with triorganotin oximes |
-
2019
- 2019-05-06 CN CN201910369841.2A patent/CN110183483A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282672A (en) * | 1962-04-09 | 1966-11-01 | Monsanto Co | Method for preventing plant growth |
US3419662A (en) * | 1962-04-09 | 1968-12-31 | Monsanto Co | Method of inhibiting the growth of bacteria and fungi with triorganotin oximes |
Non-Patent Citations (1)
Title |
---|
张复兴等: "Syntheses, Structures and Vitro Anticancer Activities of μ2-O- and μ2-Dimethylglyoximato-bridged μ3-O-Tris[di(m-fluorobenzyl)tin] Bis(dimethylglyoximate)", 《结构化学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110128466A (zh) | 一种三(2-甲基-2-苯基)丙基锡3-吲哚丁酸酯配合物及制备方法与应用 | |
Adeyemi et al. | Synthesis, characterization and biological activities of organotin (IV) diallyldithiocarbamate complexes | |
CN104177402B (zh) | 一种多取代苯甲酸有机锡配合物及制备方法与应用 | |
Adeyemi et al. | Synthesis, characterization and antimicrobial studies of organotin (IV) complexes of N-methyl-N-phenyldithiocarbamate | |
Roy et al. | Synthesis, characterization, crystal structures and in vitro antimicrobial activities of triorganotin (IV) complexes of azo-dicarboxylates | |
Patel et al. | Cu (II) and Ni (II) complexes of coumarin derivatives with fourth generation flouroquinolone: synthesis, characterization, microbicidal and antioxidant assay | |
Mehmood et al. | Synthetic stratagem, characterization and biocidal applications of triorganotin (IV) complexes derived from hydrazide/hydrazone analogues | |
Marques et al. | New gold (I) and silver (I) complexes of sulfamethoxazole: Synthesis, X-ray structural characterization and microbiological activities of triphenylphosphine (sulfamethoxazolato-N2) gold (I) and (sulfamethoxazolato) silver (I) | |
Hussain et al. | Synthesis, spectroscopy, single crystal XRD and biological studies of multinuclear organotin dicarboxylates | |
Abd El-Hady et al. | (E)-3-(2-(furan-ylmethylene) hydrazinyl)-3-oxo-N-(thiazol-2yl) propanamide complexes: Synthesis, characterization and antimicrobial studies | |
Roy et al. | Synthesis, structural characterization and antimicrobial activities of diorganotin (IV) complexes with azo-imino carboxylic acid ligand: Crystal structure and topological study of a doubly phenoxide-bridged dimeric dimethyltin (IV) complex appended with free carboxylic acid groups | |
CN108997410A (zh) | 一种三(邻溴苄基)锡-2-噻吩甲酸酯及制备方法与应用 | |
Arafat et al. | Preparation, characterization, and antimicrobial activities of bimetallic complexes of sarcosine with Zn (II) and Sn (IV) | |
Hussain et al. | Synthesis, spectroscopic characterization, X-ray crystal structure and biological activities of homo-and heterobimetallic complexes with potassium-1-dithiocarboxylatopiperidine-4-carboxylate | |
Tariq et al. | Synthesis, spectroscopic, X-ray crystal structure, biological and DNA interaction studies of organotin (IV) complexes of 2-(4-ethoxybenzylidene) butanoic acid | |
İlkimen et al. | The new salt of 2-amino-3-methylpyridine with dipicolinic acid and its metal complexes: Synthesis, characterization and antimicrobial activity studies | |
Tariq et al. | Catalytic, biological and DNA interaction studies of 3-(4-cyanophenyl)-2-methylacrylate organotin (IV) carboxylates derivatives: Synthesis, spectroscopic characterization and X-ray structures | |
Sedaghat et al. | Synthesis, structural characterization and antibacterial activity of diorganotin (IV) complexes with ONO tridentate Schiff bases containing pyridine ring | |
CN110183483A (zh) | 一种双[三(2-甲基-2-苯基)丙基锡]丁二酮肟配合物及制备方法与应用 | |
Vargová et al. | New silver (I) pyridinecarboxylate complexes: synthesis, characterization, and antimicrobial therapeutic potential | |
Matela et al. | Reactions of tin-and triorganotin (IV) isopropoxides with thymol derivative: Synthesis, characterization and in vitro antimicrobial screening | |
Lu et al. | Synthesis and biological activity of pyridine acylhydrazone derivatives of isopimaric acid | |
CN110183484A (zh) | 一种二(硫代水杨酸甲酯)二(邻氯苄基)锡配合物及制备方法与应用 | |
Zhang et al. | Studies on antimicrobial effects of four ligands and their transition metal complexes with 8-mercaptoquinoline and pyridine terminal groups | |
Bomfim Filho et al. | Syntheses, characterization and antifungal activity of novel dimethylbis (NR-sulfonyldithiocarbimato) stannate (IV) complexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190830 |
|
RJ01 | Rejection of invention patent application after publication |